Genetic investigation of Nordic patients with complement-mediated kidney diseases
(2023) In Frontiers in Immunology 14.- Abstract
- Background
Complement activation in atypical hemolytic uremic syndrome (aHUS), C3 glomerulonephropathy (C3G) and immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) may be associated with rare genetic variants. Here we describe gene variants in the Swedish and Norwegian populations.
Methods
Patients with these diagnoses (N=141) were referred for genetic screening. Sanger or next-generation sequencing were performed to identify genetic variants in 16 genes associated with these conditions. Nonsynonymous genetic variants are described when they have a minor allele frequency of Results
In patients with aHUS (n=94, one also had IC-MPGN) 68 different genetic variants or deletions were identified in 60... (More) - Background
Complement activation in atypical hemolytic uremic syndrome (aHUS), C3 glomerulonephropathy (C3G) and immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) may be associated with rare genetic variants. Here we describe gene variants in the Swedish and Norwegian populations.
Methods
Patients with these diagnoses (N=141) were referred for genetic screening. Sanger or next-generation sequencing were performed to identify genetic variants in 16 genes associated with these conditions. Nonsynonymous genetic variants are described when they have a minor allele frequency of Results
In patients with aHUS (n=94, one also had IC-MPGN) 68 different genetic variants or deletions were identified in 60 patients, of which 18 were novel. Thirty-two patients had more than one genetic variant. In patients with C3G (n=40) 29 genetic variants, deletions or duplications were identified in 15 patients, of which 9 were novel. Eight patients had more than one variant. In patients with IC-MPGN (n=7) five genetic variants were identified in five patients. Factor H variants were the most frequent in aHUS and C3 variants in C3G. Seventeen variants occurred in more than one condition.
Conclusion
Genetic screening of patients with aHUS, C3G and IC-MPGN is of paramount importance for diagnostics and treatment. In this study, we describe genetic assessment of Nordic patients in which 26 novel variants were found. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/160ec5ab-1538-424c-81f8-5ef24c15ede2
- author
- Rydberg, Viktor ; Aradottir, Sigridur Sunna LU ; Kristoffersson, Ann-Charlotte LU ; Svitacheva, Naila LU and Karpman, Diana LU
- organization
- publishing date
- 2023
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Frontiers in Immunology
- volume
- 14
- article number
- 1254759
- publisher
- Frontiers Media S. A.
- external identifiers
-
- pmid:37744338
- scopus:85171865371
- ISSN
- 1664-3224
- DOI
- 10.3389/fimmu.2023.1254759
- language
- English
- LU publication?
- yes
- id
- 160ec5ab-1538-424c-81f8-5ef24c15ede2
- date added to LUP
- 2023-09-11 17:10:11
- date last changed
- 2023-12-19 04:01:36
@article{160ec5ab-1538-424c-81f8-5ef24c15ede2, abstract = {{Background<br/>Complement activation in atypical hemolytic uremic syndrome (aHUS), C3 glomerulonephropathy (C3G) and immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) may be associated with rare genetic variants. Here we describe gene variants in the Swedish and Norwegian populations.<br/>Methods<br/>Patients with these diagnoses (N=141) were referred for genetic screening. Sanger or next-generation sequencing were performed to identify genetic variants in 16 genes associated with these conditions. Nonsynonymous genetic variants are described when they have a minor allele frequency of Results<br/>In patients with aHUS (n=94, one also had IC-MPGN) 68 different genetic variants or deletions were identified in 60 patients, of which 18 were novel. Thirty-two patients had more than one genetic variant. In patients with C3G (n=40) 29 genetic variants, deletions or duplications were identified in 15 patients, of which 9 were novel. Eight patients had more than one variant. In patients with IC-MPGN (n=7) five genetic variants were identified in five patients. Factor H variants were the most frequent in aHUS and C3 variants in C3G. Seventeen variants occurred in more than one condition.<br/>Conclusion<br/>Genetic screening of patients with aHUS, C3G and IC-MPGN is of paramount importance for diagnostics and treatment. In this study, we describe genetic assessment of Nordic patients in which 26 novel variants were found.}}, author = {{Rydberg, Viktor and Aradottir, Sigridur Sunna and Kristoffersson, Ann-Charlotte and Svitacheva, Naila and Karpman, Diana}}, issn = {{1664-3224}}, language = {{eng}}, publisher = {{Frontiers Media S. A.}}, series = {{Frontiers in Immunology}}, title = {{Genetic investigation of Nordic patients with complement-mediated kidney diseases}}, url = {{http://dx.doi.org/10.3389/fimmu.2023.1254759}}, doi = {{10.3389/fimmu.2023.1254759}}, volume = {{14}}, year = {{2023}}, }